- Home
- ALVO vs CPRX Comparison
ALVO vs CPRX Comparison
Compare ALVO & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVO
- CPRX
- Stock Information
- Founded
- ALVO 2013
- CPRX 2002
- Country
- ALVO Luxembourg
- CPRX United States
- Employees
- ALVO N/A
- CPRX N/A
- Industry
- ALVO Biotechnology: Pharmaceutical Preparations
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ALVO Health Care
- CPRX Health Care
- Exchange
- ALVO Nasdaq
- CPRX Nasdaq
- Market Cap
- ALVO 2.5B
- CPRX 2.9B
- IPO Year
- ALVO N/A
- CPRX 2006
- Fundamental
- Price
- ALVO $9.38
- CPRX $22.76
- Analyst Decision
- ALVO Buy
- CPRX Strong Buy
- Analyst Count
- ALVO 1
- CPRX 7
- Target Price
- ALVO $18.00
- CPRX $32.29
- AVG Volume (30 Days)
- ALVO 140.4K
- CPRX 1.0M
- Earning Date
- ALVO 05-07-2025
- CPRX 05-07-2025
- Dividend Yield
- ALVO N/A
- CPRX N/A
- EPS Growth
- ALVO N/A
- CPRX 178.13
- EPS
- ALVO 0.34
- CPRX 1.57
- Revenue
- ALVO $587,890,000.00
- CPRX $534,645,999.00
- Revenue This Year
- ALVO $33.92
- CPRX $15.59
- Revenue Next Year
- ALVO $45.74
- CPRX $8.90
- P/E Ratio
- ALVO $27.67
- CPRX $14.51
- Revenue Growth
- ALVO 413.92
- CPRX 29.97
- 52 Week Low
- ALVO $7.35
- CPRX $14.47
- 52 Week High
- ALVO $14.65
- CPRX $26.16
- Technical
- Relative Strength Index (RSI)
- ALVO 58.67
- CPRX 46.01
- Support Level
- ALVO $7.90
- CPRX $22.94
- Resistance Level
- ALVO $8.50
- CPRX $25.01
- Average True Range (ATR)
- ALVO 0.39
- CPRX 0.83
- MACD
- ALVO 0.18
- CPRX -0.05
- Stochastic Oscillator
- ALVO 67.72
- CPRX 46.56
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).